This variant is located in the kinase domain of CHEK2, a critical functional domain where pathogenic missense variants are known to cluster.¹ The variant was directly studied in at least one publication (Baloch et al.) examining CHEK2 missense mutations and breast cancer risk, but functional assay results are conflicting across studies — some report reduced kinase activity while others show wild-type-like function.² The variant is present in gnomAD v4.1 at an allele frequency of 0.038% (606 alleles, including 3 homozygotes), which exceeds the PM2 threshold of <0.1% and is notable but below BS1 threshold of >0.3%.³ In silico tools do not support a pathogenic role: REVEL score 0.337, BayesDel score -0.013, and SpliceAI max delta 0.05 all indicate a likely benign or indeterminate effect.⁴ ClinVar classification is conflicted between Uncertain significance (19 clinical laboratories) and Likely benign (13 clinical laboratories), with overall review status of criteria provided, single submitter (1-star).⁵ One ClinVar submitter reports non-segregation of this variant with disease in a family and observation in unaffected controls, but the primary literature could not be verified.⁶ Overall, pathogenic evidence (PM1_moderate, PS3_supporting) is balanced by benign evidence (BP4_supporting), resulting in a classification of Uncertain Significance.